JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

REVIEW ON PHENOXYBENZAMIN CAPSULES

[1]POMMALA NAGAVENI, [2]DEVIREDDY HARSHITHA, [3]KASIMEDU SARAVANA KUMAR, [4]RACHAMREDDY SUPRIYA, [5]ULAVA MAHENDRA CHOWDARY, [6]GAJULA VINUTHNA GRACE

[1]Academic consultant, [2]Student,[3] Academic director, [4]Student, [5]Student, [6]Student

[1]Department of pharmaceutics

SVU College of pharmaceutical Sciences, Tirupati (517502).

Address of the correspondence: POMMALA NAGAVENI

ABSTRACT:

Ten milligrams of USP phenoxybenzamine hydrochloride are contained in each capsule. Talc and lactose anhydrous are examples of inactive substances. N-(2-chloroethyl) -N-(1-methyl-2-phenoxyethyl) benzylamine hydrochloride.

With a molecule weight of 340.3 phenoxybenzamine hydrochloride is a white, solid, crystalline powder that melts at temperatures between 136 degree and 141 degree celsius. It is insoluble in ethyl acetate, easily soluble in methanol, and soluble in acetone. A wating the USP organic impurities test.

PHENOXYBENXZMINE CAPSULES – CLINICAL PHARMACOLOGY

The long -acting adrenergic alpha-receptors – blocking drug phenoxybenzamine hydrochloride can cause and sustain chemical sympathectomy when taken oral. It decreases erect and supine blood pressure and improves blood flow to skin, mucosa, and abdominal viscera. It doesn't impact the parasympathetic nervous system. It seems that 20-30% of phenoxybenzamine taken orally is absorbed in its active state. phenoxybenzamine hydrochloride taken orally has an unknown half – life, but the substance used intravenously has a half – life of roughly 24 hours. Intravenous injection has demonstrable benefits that last for at least three to four days, while daily dosing has cumulative effect that last for almost a week. with us your personal information is completely protected your information is never saved with outside parties.[1]

INDICATION AND USAGE FOR PHENOXYBENZAMINE CAPSULES

In the treatment of pheochromocytoma, phenoxybenzamine hydrochloride capsules, USP, are advised to manage episodes of sweating and hypertension; if tachycardia is signification, a beta – blocking medication may be required concurrently.[5]

CONTRAINDICATION

Circumstances where a drop in blood pressure would not desirable; medication or component hypersensitivity.

WARNINGS

Alpha- adrenergic inhibition caused by phenoxybenzamine hydrochloride doesn't interfere with beta-adrenergic receptors. Therefore, substances that activate both kinds of receptors may cause tachycardia and an inflate hypotensive response.

PRECAUTIONS:

General use caution administering to patients who have significant renal damage or cerebral or coronary arteriosclerosis. The symptoms of respiratory infections may worsen due to an adrenergic blocking action.[5]

DRUG INTERACTIONS 2:

Phenoxybenzamine hydrochloride may causes tachycardia and an increased hypotensive response when it interacts with substances activate alpha -and beta-adrenergic receptors, such as epinephrine. Phenoxybenzamine hydrochloride prevents levarterenol from causing hyperthermia and reserpine from causing hypothermia.

Text input outcome original content get rid of plagiarism to make the content distinctive, reward it. There have been case reports of human cancer following prolonged phenoxybenzamine treatment. Therefore, it is not advised to use Phenoxybenzamine for an extended period of time 3, 4. Before prescribing this medication carefully consider the advantages and disadvantages. In the mouse lymphoma assay and the Ames Test, Phenoxybenzamine hydrochloride demonstrated mutagenic activity in vivo. Peritoneal sarcoma developed in rat and mice after Phenoxybenzamine hydrochloride was repeatedly administered intraperitoneally three times a week for a maximum of 52 weeks. Rats given oral medication for up to two years developed non-glandular stomach and small intestine cancers, along with ulcerative and / or erosive gastritis of the

PREDNANCY- TERATOGENIC EFFECTS – PREGNANCY CATEGARY:

Phenoxybenzamine hydrochloride has not to been the subject of sufficient animal reproductive studies Additional, it is known if giving phenoxybenzamine hydrochloride to a pregnant women could harm the foetus. A pregnant women should only receive phenoxybenzamine hydrochloride if it is absolutely necessary.

Nursing Mother:

When this medication is eliminated in human milk is unknown. the importance of the medication to the mother should be taken into consideration when deciding whether to stop nursing or to stop taking phenoxybenzamine hydrochloride due to the possibility of severe adverse effects and the fact that many medications are elimination in human milk. [6]

Pediatric use:

Use in pediatric there is no demonstrated safety or efficacy in pediatric patients.

ADVERSE REACTIONS / SIDE EFFECTS:

Although the following adverse effects have been noted, their frequency cannot be estimated due to a lack of evidence. * Autonomic Nervous system: miosis, nasal congestion, tachycardia, postural hypotension, and ejaculation inhibition. *These alleged side effects are actually signs of adrenergic blockade, and their severity varies. miscellaneous; Fatigue, sleepiness, and gastrointestinal discomfort. [5]

OVER DOSAGE:

SYMPTOMS: There are mostly caused by the sympathetic nervous system and circulating adrenaline being blocked. there could include vomiting, lethargy, shock, tachycardia, especially postural tachycardia, and postural hypotension, which cause light headedness or fainting. [5]

TREATMENT:

Stop taking the medication as soon as overdosage symptoms appear. One of the most important factors is how to treat circulatory failure, if it exists. when a slight overdose occurs, cerebral circulation is typically restored by lying down with the legs raised. The standard procedures to prevent shock should be implemented in the more severe instance. Standard pressor agents don’t work. Because it stimulates both alpha and beta receptors, epinephrine is contraindicated. When alpha receptors are inhibition epinephrine delivery results in vasodilation and a subsequent decrease in blood pressure, a phenomenon known as epinephrine reversal. Because the effects of on overdose are protracted, the patient

many need to be maintained flat for 24 hours or more. An abdominal binder and leg bandages could reduce the duration of incapacity.

PHENOXYBENZAMINE CAPSULE DOSAGE AND ADMINISTRATION:

Each patients need should be taken into consideration when adjusting the dosage. Until the desired effect is achieved or the blockade adverse effect become problematics, small beginning doses should be gradually raised. prior to implementing another increment, the patients should be monitored on that level following each one. The dosage should be increased until objective improvement and /or symptomatic relief are achieved, but not to be extent that blockade adverse effects become problematic. 10 mg of phenoxybenzamine hydrochloride twice a daily at first. Until an idea dosage is reached, as determined by blood pressure control, the dosage should be raised every other day, often to 20 to 40 two or three times daily. it is not advised to taken phenoxybenzamine for an extended period of the[7] [8][9][10][11]

STORAGE AND HANDLING:

Store between 20 degrees and 25 degrees Celsius (68sdegree 77degree F); exceptions are allowed between 15 degree and 30 degree Celsius, (59 degree and 86 degree F). The USP controlled room temperature is also mentioned. [1]

HOW IS PHENOXYBENZAMINE CAPSULES SUPPLIED

White to off. White powder is contained in each USP phenoxybenzamine hydrochloride capsules, which has a scarlet trans coloured cap and a body imprinted with PAR on the cap and 260 and on the body. 100 bottles of 10 mg phenoxybenzamine hydrochloride USP capsules (NDC 49884-038- 01). [1]

REFRENCES

1.Goodman LS, Gilman A. The pharmacological basis of therapeutics. Macmillan, New York; 1970.

2. Martin, E.W.: Drug Interactions Index 1978/1979, Philadelphia, J.B. Lippincott Co., 1978, pp. 209-210.

3. Nettesheim O, Hoffken G, Gahr M, Breidert M: Haematemesis and dysphagia in a 20-year-old woman with congenital spine malformation and situs inversus partialis [German]. Zeitschrift fur Gastroenterologie. 2003; 41(4):319-24.

4. Vaidyanathan S, Mansour P, Soni BM, Hughes PL, Singh G: Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy. Spinal Cord. 2006;44(3):188-91. 5.National Toxicology PROGRAM. Phenoxybenzamine hydrochloride. Rep Carcinog.2001;12:3445-5

6.Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006 Suppl 4 (Suppl 4) :S3-9. 7. Ramachandra R, Rewari V. Current perioperative management of pheochromocytomas. India J Urol. 2017 Jan-Mar;33(1):19-25.

8. Te AE. A modern rationale for the use of phenoxybenzamine in urinary track disorders and other conditions. Clin Ther. 2002 Jan;24(6):851-61; discussion 837.

9.Hack HA, Brown TC Preoperative management of phaeochromocytoma-a paediatric perspective. Anaesth Intensive Care. 2999 Feb;27(1):112-3. 10.Darr R, Lenders JW, Hofbaurer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma – update on disease management. Their Adv Endocrinol Metab. 2012 Feb;3(1):11-26. 11.Romeo M, Kapur G, Baracco R, Valentini RP, Matto TK, Jain A. Treatment of Hypertension in Children with Catecholamine-Secreting Tumors: A Systematic Approach. J Clin Hypertens (Greenwich). 2015 Sep;17(9):720-5.